A new antibody in rheumatoid arthritis targeting glycated IgG: IgM anti-IgG-AGE

British Journal of Rheumatology

Volumn 37, Issue 12, 1998, Pages 1307-1314

  Ligier, S ^a   Fortin, P R ^a   Newkirk, M M ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Advanced glycation end products; Autoantibody; Diabetes; Rheumatoid factor; Vasculitis

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AUTOANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M ANTIBODY; NITROBLUE TETRAZOLIUM; RHEUMATOID FACTOR;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CASE REPORT; COLORIMETRY; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERGLYCEMIA; IMMUNOBLOTTING; MALE; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS;

AGED; ANTIBODY SPECIFICITY; ANTIGEN-ANTIBODY COMPLEX; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; IMMUNOBLOTTING; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RHEUMATOID FACTOR; VASCULITIS;

EID: 0032415432     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Robbins DL, Feigal DW Jr, Leek JC. Relationship of serum IgG rheumatoid factor and disease activity in rheumatoid arthritis. J Rheumatol 1986;13:259-62.
2. Eberhardt, KB, Truedsson L, Petersson H, Svensson B, Stigsson L, Eberhardt JL et al. Disease activity and joint damage progression in early rheumatoid arthritis: relation to IgG, IgA and IgM rheumatoid factors. Ann Rheum Dis 1990;49:906-9.
3. Teitsson I, Withrington RH, Seifert MH, Valdimarsson H. Prospective study of early rheumatoid arthritis. 1. Prognostic value of IgA rheumatoid factor. Ann Rheum Dis 1984;43:673-6.
4. Tarkowski A, Nilsson LA. Isotype-specific measurement of rheumatoid factor with reference to clinical features of rheumatoid arthritis. J Clin Lab Immunol 1983; 12:129-35.
5. van Schaardenburg D, Hazes JMW, de Boer A, Zwinderman AH, Meijers KAE, Breedveld FC. Outcome of rheumatoid arthritis in relation to age and rheumatoid factor at diagnosis. J Rheumatol 1993;20:45-52.
6. Wagner U, Kaltenhäuser S, Sauer H, Arnold S, Seidel W, Häntzschel H et al. HLA markers and prediction of clinical course and outcome in rheumatoid arthritis. Arthritis Rheum 1997;40:341-51.
7. Weyand CM, Hicok KC, Conn DL, Goronzy JJ. The influence of HLA-DRß1 genes on disease severity in rheumatoid arthritis. Ann Intern Med 1992;117:801.
8. Nepom GT, Byers P, Seyfried C, Healey LA, Wilske KR, Stage D et al. HLA genes associated with rheumatoid arthritis: identification of susceptibility alleles using specific oligonucleotide probes. Arthritis Rheum 1989; 32:15-21.
9. Takahashi M, Suzuki M, Kushida K, Miyamoto S, Inoue T. Relationship between pentosidine levels in serum and urine and activity in rheumatoid arthritis. Br J Rheumatol 1997;36:637-42.
10. Bucala R, Cerami A. Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 1992;23:1-34.
11. Menini T, Gugliucci A, Sodahlon YK, Stahl AJC, Blickle JF, Brogard JM. Glycated immunoglobulin M in diabetic patients. Ann Biol Chem 1993;50:887-91.
12. Kaneshige H. Non-enzymatic glycosylation of serum IgG and its effect on antibody activity in patients with diabetes mellitus. Diabetes 1987;36:822-8.
13. Dolhofer-Bliesener R, Gerbitz KD. Effect of nonenzymatic glycation on the structure of immunoglobulin G. Biol Chem Hoppe-Seyler 1990;371:693-7.
14. Sasaki Y, Mori T, Shiiki H, Dohi K, Ishikawa H. Non-enzymatic glycosylation of mouse monoclonal antibody reduces its binding activity to antigen. Clin Chim Acta 1993;220:119-21.
15. Kennedy DM, Skillen AW, Self CH. Glycation of monoclonal antibodies impairs their ability to bind antigen. Clin Exp Immunol 1994;98:245-51.
16. Newkirk MM, Fournier MJ, Shiroky J. Rheumatoid factor avidity; identification of pathogenic RFs which correlate with Gal(o) glycoform of IgG in patients with rheumatoid arthritis. J Clin Immunol 1995;15:250-7.
17. Pokharna HK, Monnier V, Boja B, Moskowitz RW. Lysyl oxidase and Maillard reaction-mediated cross-links in ageing and osteoarthritic rabbit cartilage. J. Bone Joint Res 1995;13:13-21.
18. Mashiba S, Uchida K, Okuda S, Tomita S. Measurement of glycated albumin by the nitroblue tetrazolium colonmetric method. Clin Chim Acta 1992;212:3-15.
19. Johnson R, Metcalf PA, Baker JR. Fructosamine: a new approach to the estimation of serum glycosylation. An index of diabetic control. Clin Chim Acta 1982; 127:87-95.
20. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680-5.
21. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979;76:4350-4.
22. Mizutari K, Ono T, Ikeda K, Kayashima K, Horiuchi S. Photo-enhanced modification of human skin elastin in actinic elastosis by Nε (carboxymethyl)lysine, one of the glycoxidation products of the Maillard reaction. J Invest Dermatol 1997;108:797-802.
23. Rodriquez-Garcia J, Requena JR, Rodriguez-Segade R. Increased concentrations of serum pentosidine in rheumatoid arthritis. Clin Chem 1998;44:250-5.
24. Lunec J, Halloran SP, White AG, Dormandy TL. Free-radical oxidation (peroxidation) products in serum and synovial fluid in rheumatoid arthritis. J Rheumatol 1981;8:233-45.
25. Miesel R, Murphy MP, Kroger H. Enhanced mitochondrial radical production in patients with rheumatoid arthritis correlates with elevated levels of tumor necrosis factor alpha in plasma. Free Radical Res 1996;25:161-9.
26. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991;40:405-12.
27. Cervantes-Laurean D, Jacobson EL, Jacobson MK. Glycation and glycoxidation of histones by ADP-ribose. J Biol Chem 1996;271:10461-9.
28. Svenson KLG, Lundqvist G, Wide L, Hällgren R. Impaired glucose handling in active rheumatoid arthritis: relationship to the secretion of insulin and counter-regulatory hormones. Metabolism 1987;36:940-3.
29. Svenson KLG, Pollare T, Lithell H, Hällgren R. Impaired glucose handling in active rheumatoid arthritis: relationship to peripheral insulin resistance. Metabolism 1988;37:125-30.
30. Svenson KLG, Lundqvist G, Wide L, Hällgren R. Impaired glucose handling in active rheumatoid arthritis: effects of corticosteroids and anti rheumatic treatment. Metabolism 1987;36:944-8.
31. Schmidt AM, Hori O, Brett J, Yan SD, Wautier J-L, Stern D. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 1994;14:1521-8.
32. Makita Z, Vlassara H, Cerami A, Bucala R. Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 1992;267:5133-8.
33. Drake JR, Webster P, Cambier JC, Mellman I. Delivery of B cell receptor-internalised antigen to endosomes and Class II vesicles. J Exp Med 1997;186:1299-306.
34. Kemper JW, Baggenstoss AH, Slocumb CH. The relationship of therapy with cortisone to the incidence of vascular lesions in rheumatoid arthritis. Ann Intern Med 1957:46:831-51.
35. Niwa T, Miyazaki S, Katsuzakil T. Immunohistochemical detection of advanced glycation end products in dialysis-related amyloidosis. Kidney Int 1995;48:771-8.
36. Miyata T, Maeda K. New aspects in the pathogenesis of dialysis-related amyloidosis: role of ß2-microglobulin modified with advanced glycation end products in bone and joint destruction. Nephrol Dial Transplant 1996; 11(suppl. 2):140-3.